The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback